New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 stu... See more
Thomas Kim to join S&P Global October 19, 2026 Steve Kemps to retire at the end of the year S&P Global (NYSE: SPGI) today announced the appointment of Thomas Kim as the company's new Chief Legal Officer, effective October 19, 2026. Mr. Kim will re... See more
Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile Johnson & Johnson ... See more
NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in participants w... See more
SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSESTON... See more
